Short answer: A medical device classified as Class II in the United States is not automatically Class IIa or IIb in the EU or UK. Each market applies its own classification rules and market-access requirements. In the US, most Class II devices require FDA 510(k) clearance unless they are exempt. In the EU, devices are classified as Class I, IIa, IIb, or III under the EU MDR, with Class IIa and IIb devices generally requiring notified body involvement for conformity assessment. In Great Britain, manufacturers can use UKCA under the UK framework, while CE-marked devices remain accepted under current transition arrangements through dates that depend on the device and the applicable EU legislation. MHRA registration is also required for devices placed on the GB market. Northern Ireland follows a different framework.
If you sell the same device across the US, EU, and UK, you are not managing one regulatory pathway in three places. You are managing different classifications, market-access pathways, responsible-party requirements, registrations, and lifecycle obligations for the same product.
A note on dates and requirements: Medical device regulations and implementation timelines can change. This is particularly important for Great Britain’s acceptance of CE-marked devices and the evolving UK medical device framework, as well as the phased implementation of EUDAMED. The information below reflects requirements and timelines available as of August 2026. Always confirm the latest requirements with the relevant authority before making regulatory decisions.
What “Class II” means in the United States
The FDA uses a three-tier risk classification: Class I (low risk), Class II (moderate risk), and Class III (high risk). Class II is the largest bucket and covers a wide range of devices.
There are two main routes to market for Class II devices:
- 510(k) premarket notification. The manufacturer demonstrates that the device is substantially equivalent to a legally marketed “predicate” device. Most Class II devices use this pathway, and FDA clearance is required before marketing.
- 510(k)-exempt. A subset of Class II devices (and most Class I devices) are exempt from the 510(k) requirement. These devices still require FDA establishment registration and device listing, and remain subject to general controls and any applicable special controls, but no premarket submission is filed.
A smaller set of novel low-to-moderate-risk devices with no predicate use the De Novo pathway, which can establish a new Class I or Class II classification. Higher-risk devices follow PMA (premarket approval).
US establishment registration is an annual requirement, and device listings must be kept current. A 510(k) clearance does not function as an annual renewal, but certain significant device changes, including changes that could affect safety or effectiveness or involve a new intended use, may require a new 510(k).
What “Class II” maps to in the EU under MDR
The EU does not have a “Class II” tier. Under Regulation (EU) 2017/745 (EU MDR), devices are classified as Class I, Class IIa, Class IIb, or Class III, based on rules in Annex VIII covering duration of contact, invasiveness, and the part of the body affected.
A device that is Class II in the US will typically fall into Class IIa or Class IIb in the EU, but this is a mapping you have to work out rule by rule, not an assumption. The route to market is CE marking:
- Class I (non-sterile, non-measuring, non-reusable surgical): self-declaration; the manufacturer issues the Declaration of Conformity without a notified body.
- Class IIa, IIb, and III: require a notified body to assess conformity (the scope of assessment increases with risk class) before the CE mark can be applied.
For a device that falls into Class IIa or IIb under the EU MDR, manufacturers generally need to prepare technical documentation, demonstrate conformity with the General Safety and Performance Requirements (GSPR), undergo the applicable notified body conformity assessment, register the relevant actors and device information in EUDAMED, and issue an EU Declaration of Conformity. Manufacturers outside the EU also generally need an EU Authorized Representative.
As of May 28, 2026, the Actor Registration, UDI/Device Registration, Notified Bodies & Certificates, and Market Surveillance modules of EUDAMED are mandatory to use. You can read more on our EU MDR overview.
What changes in Great Britain: UKCA, CE Marking, and MHRA Registration
Since Brexit, Great Britain (England, Scotland, and Wales) operates under the UK Medical Devices Regulations 2002 (UK MDR), administered by the MHRA. For manufacturers placing devices on the GB market, the current framework involves MHRA registration plus an applicable conformity-marking route.
UKCA: Manufacturers can use the UKCA marking to demonstrate conformity with the UK MDR. Manufacturers based outside the UK generally need a UK Responsible Person to act on their behalf.
CE marking: CE-marked medical devices continue to be accepted in Great Britain under current transitional arrangements. For general medical devices compliant with the EU MDD or AIMDD, CE-marked devices can generally be placed on the GB market until the earlier of certificate expiry or June 30, 2028. Devices compliant with the EU MDR can generally continue to be placed on the GB market until June 30, 2030, subject to the applicable conditions.
The UK government consulted in 2026 on proposals for indefinite recognition of CE-marked devices, but those proposals should not be presented as the current final requirement.
Northern Ireland is different. Devices placed on the Northern Ireland market are subject to EU MDR/IVDR requirements, with additional UK-specific considerations depending on the conformity assessment route
US vs EU vs UK at a glance
| Dimension | United States (FDA) | European Union (MDR) | United Kingdom — GB (MHRA) |
|---|---|---|---|
| Classification | Class I, II, III | Class I, IIa, IIb, III | Class I, IIa, IIb, III |
| Typical Class II pathway | 510(k) unless exempt | MDR conformity assessment; notified body generally required for IIa/IIb | UKCA or qualifying CE route under transition |
| Market-access marking | FDA clearance or exemption; no CE-style mark | CE mark | UKCA or CE during applicable transition |
| Key conformity document | 510(k) submission | Declaration of Conformity + technical file (GSPR) | Declaration of Conformity (UKCA) |
| In-country / regional role | US Agent (for foreign firms) | EU Authorized Representative | UK Responsible Person |
| Database / registry | FDA registration & listing; GUDID (UDI) | EUDAMED (UDI/EUDAMED) | MHRA device registration |
| Renewal driver | Annual establishment registration | Notified body certificate validity | Registration upkeep + transition deadlines |
This table is a planning aid, not regulatory advice; confirm specifics for your device against current guidance.
Why the same device creates three different work streams
A few practical traps follow from the table:
- Classification doesn’t carry over. US Class II can land in EU/UK Class IIa or IIb, which changes whether and how a notified body is involved. You map it per jurisdiction.
- The “responsible party” differs in each market. US Agent, EU Authorized Representative, UK Responsible Person, each a distinct relationship to maintain.
- The ongoing obligations are different. US establishment registration is annual; EU notified body certificates have defined validity periods and EUDAMED obligations now apply to the first four modules; and Great Britain combines MHRA registration requirements with applicable conformity-marking and transition obligations.
- A single product change can create different regulatory work in each market. A labeling, design, software, or intended-use change may require a new 510(k) assessment in the US, an MDR conformity or technical documentation assessment in the EU, and corresponding UK conformity or registration actions in Great Britain. The regulatory question is therefore not simply “What changed?” but “Which markets, registrations, submissions, and obligations does the change affect?” This is where change-impact assessment matters across markets.
How teams track US, EU, and UK registrations in one place
Most regulatory teams start by managing this in spreadsheets, one tab per market, color-coded renewal dates, a shared drive of technical files. That holds until the portfolio grows, the renewal calendars drift apart, and a change in one market quietly creates obligations in the other two.
A Regulatory Information Management (RIM) platform can connect the same product across its different regulatory identities, linking submissions, registrations, responsible parties, documents, certificates, and renewal or expiration dates to a common product record.
This becomes especially valuable when regulatory teams are managing the same products across multiple markets and need to understand how a change in one jurisdiction affects obligations elsewhere.
RegDesk is one example of a device-native RIM platform (built around medical-device and IVD workflows rather than adapted from pharma). A few specifics relevant to multi-market Class II work:
- Registration and renewal tracking across markets, so US annual listings, EU certificate expirations, and UK registration deadlines surface before they lapse rather than after. RegDesk customers report zero missed registration renewals. See registration & renewal tracking.
- AI-assisted submission preparation that helps auto-prepare jurisdiction-specific outputs, GSPR mapping, Essential Principles, Declarations of Conformity, and country dossiers, by reusing data already entered, which is where RegDesk customers report 35+ hours saved per submission, 70% reduction in time spent finding regulatory information, and zero missed registration renewals.
- Human-curated regulatory intelligence across 120+ markets, so when a UK transition date moves or an EU requirement changes, the affected products and registrations are flagged. (Curated by an in-country regulatory expert network, not generic newsletters.)
- UDI support for both FDA GUDID and EU EUDAMED, plus SOC 2 and 21 CFR Part 11 compliance with audit trails and e-signatures.
According to a Forrester Total Economic Impact study commissioned by RegDesk (October 2025), a composite organization based on interviewed customers realized 196% ROI over three years, $2.6M net present value, and payback in under six months. RegDesk has also been recognized by Gartner and Gens & Associates in regulatory information management research.
When You May Not Need RIM Software Yet
A dedicated RIM is not always the right call:
- If you sell in only one of the three markets and have a small, stable portfolio, a well-maintained spreadsheet and your eQMS may be enough for now.
- If you have a single device with no near-term renewals or planned changes, the coordination problem this post describes barely exists yet.
- If your immediate gap is a single submission rather than ongoing multi-market tracking, a focused submission effort, possibly with outside regulatory support, may address the need without new software.
The calculus changes once you are managing the same products across two or more markets, the renewal calendars start to diverge, or a change in one jurisdiction routinely creates work in the others. That’s the point where holding the US, EU, and UK in disconnected spreadsheets stops scaling, and where a device-native RIM becomes worth evaluating.
Image Credits: Magnific
Frequently asked questions
Is a US Class II device automatically Class IIa or IIb in the EU? No. The EU classifies under its own MDR rules (Annex VIII), so a US Class II device must be classified independently and may land in Class IIa or Class IIb depending on factors like invasiveness and duration of contact. The mapping has to be worked out per device.
What’s the difference between a 510(k) and a 510(k)-exempt device? A 510(k) device requires a premarket notification demonstrating substantial equivalence to a predicate, and FDA clearance before marketing. A 510(k)-exempt device does not require that submission, but still requires FDA establishment registration and device listing and remains subject to applicable controls.
Do I still need a UKCA mark if my device is CE marked? During a transition period, Great Britain has continued to accept CE-marked devices, with the move to UKCA pushed back more than once. Because these dates have changed repeatedly, confirm the current MHRA position for your device type rather than relying on a fixed deadline. Northern Ireland follows separate rules.
Who is my “responsible party” in each market? The US uses a US Agent for foreign establishments, the EU requires an EU Authorized Representative for non-EU manufacturers, and Great Britain requires a UK Responsible Person. These are three separate roles to appoint and maintain.
How do teams keep US, EU, and UK renewals from slipping? By holding each market’s registration, status, and renewal date against a single product record, typically in a RIM platform with registration and renewal tracking. RegDesk customers report zero missed registration renewals using this approach.
Can one platform manage submissions and registrations across the US, EU, and UK? Yes, a multi-market RIM is designed to manage registrations, submissions, and renewals across many jurisdictions at once. RegDesk provides registration tracking and AI-assisted, jurisdiction-specific submission preparation across 120+ markets.
